Ardelyx President and CEO Michael Raab sold 41,666 shares worth approximately $243,000 on March 16, 2026, as part of a routine 10b5-1 trading plan. The sale represented 2.21% of his holdings and followed an option exercise. Despite recent legal headwinds abating and a new chief medical officer appointment, the stock is down 16.57% over five years, though analysts have a $16.10 price target suggesting 170% upside potential.

Ardelyx, Inc. announced the appointment of Dr. Rajani Dinavahi as Chief Medical Officer. Dr. Dinavahi brings over two decades of healthcare and biotechnology experience, including leadership roles at Atara Biotherapeutics and Amgen. She will lead medical capabilities and pipeline advancement for the commercial-stage biopharmaceutical company.

Ardelyx, Inc. announced it will hold a conference call on February 19, 2026, to discuss full year and fourth quarter 2025 financial results and provide a business update. The call will feature commentary from executive leadership including CEO Mike Raab and CFO Sue Hohenleitner. The company has two FDA-approved commercial products (IBSRELA and XPHOZAH) and is advancing IBSRELA in Phase 3 development for chronic idiopathic constipation.

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.

Ardelyx, a biopharmaceutical company, announced that it will present data supporting its product IBSRELA (tenapanor) at the Digestive Disease Week 2025 Conference.

Ardelyx, a biopharmaceutical company, announced that it will present data on its IBS-C drug IBSRELA and results from the IBS in America 2024 survey at the upcoming Digestive Disease Week Conference.

Ardelyx, a biopharmaceutical company, announced that it will present at the TD Cowen's 45th Annual Health Care Conference on March 3, 2025. The company has two commercial products approved in the U.S. and has agreements for the development and commercialization of its product tenapanor outside the U.S.

Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.

Ardelyx, a biopharmaceutical company, announced that its executives will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024.

Rosen Law Firm is encouraging investors who purchased Ardelyx, Inc. securities between October 31, 2023 and July 1, 2024 to secure counsel before the October 15, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding its future revenue, funding requirements, and the commercial success of its phosphorus inhibitor, XPHOZAH.

Holzer & Holzer, LLC reminds investors of the October 15, 2024 lead plaintiff deadline in class action lawsuits against Symbotic Inc., Ardelyx, Inc., PDD Holdings Inc., and Sprinklr, Inc. The lawsuits allege the companies made false or misleading statements that caused shareholders to purchase their securities at artificially inflated prices.